LEO Pharma

LEO Pharma, Japan Tobacco ink license agreement for JTE-052

Wednesday, November 5, 2014 12:47 PM

LEO Pharma and Japan Tobacco (JT) have entered into a license agreement, under which LEO Pharma will obtain exclusive rights to further develop, register and market JT’s experimental JAK inhibitor, JTE-052, for topical use in dermatological indications worldwide, excluding Japan where JT retains rights.

More... »


LEO Pharma, 4SC Discovery ink exclusive research agreement

Tuesday, February 26, 2013 01:48 PM

LEO Pharma, a global pharmaceutical company specializing in dermatology, has entered into an exclusive research and license agreement with the German biotech company 4SC Discovery with the primary aim of jointly researching, developing and commercializing an oral treatment for inflammatory skin diseases such as psoriasis.

More... »


LEO Pharma unveils new scientific collaboration strategy

Wednesday, October 3, 2012 11:08 AM

LEO Pharma, a global pharmaceutical company specializing in dermatology and critical care, plans to establish five long-term, strategic research collaborations in Australia, France, Germany and the U.S. by the end of next year.

More... »

FDA approves LEO Pharma’s Picato gel

Wednesday, January 25, 2012 04:21 PM

The FDA has approved LEO Pharma’s Picato (ingenol mebutate) gel (0.015%, 0.05%) for the topical treatment of actinic keratosis (AK), a precancerous condition caused by cumulative sun exposure.

More... »

LEO Pharma and Scripps Research Institute collaborate

Tuesday, July 19, 2011 01:39 PM

LEO Pharma and The Scripps Research Institute have entered a research collaboration.

More... »


CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs